TOX high mobility group box family member 3Genealiases: CAGF9 · TNRC9
Q-omics provides the consensus-scored TOX3 profile across patient tissues and cancer cell-line models. TOX3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TOX3 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TOX3 RNA expression shows 17,682 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where TOX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOX3 survival associations across molecular data types. TOX3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOX3 RNA expression–survival associations across cancer types. High TOX3 expression shows favorable associations in KIRC, BRCA, BLCA, COAD, UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TOX3 RNA expression.
This table summarizes TOX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TOX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOX3 shows lower tumor expression in KIRC, HNSC and LUSC and higher tumor expression in BRCA, LUAD and COAD. The KIRC box plot shows higher TOX3 RNA expression in normal versus tumor tissue (log2 FC = −3.483, t-test p < 0.001).
This table shows molecular features associated with TOX3 in patient tissues and cancer cell lines. In patient samples, TOX3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TOX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BREAST.
